Trained to see patterns by analyzing thousands of chest X-rays, a computer program predicted with up to 80 percent accuracy which COVID-19 patients would develop life-threatening complications within four days, a new study finds.
New artificial intelligence technology that uses a common CT angiography (CTA) as opposed to the more advanced imaging normally required to help identify patients who could benefit from endovascular stroke therapy (EST) is being developed at UTHealth.
Researchers at Huntsman Cancer Institute have found critical new insights into how cells defend against melanoma. In a report published in Nature Communications, the team describes how an enzyme called nicotinamide phosphoribosyltransferase, or NAMPT, initiates antitumor activity. The researchers suggest that new therapies strengthening this pathway in immune cells could be the foundation for more effective treatments against melanoma.
A new study from the University of Chicago has found that the photosynthetic bacterium Synechococcus elongatus uses a circadian clock to precisely time DNA replication, and that interrupting this circadian rhythm prevents replication from completing and leaves chromosomes unfinished overnight.
Scientists have developed a novel CRISPR-based genetic sensor called a “CopyCatcher” to detect instances in which a genetic element is copied precisely from one chromosome to another in cells of a fruit fly.
By engineering a short chunk of protein, or peptide, that can prevent the attachment of human parainfluenza viruses to cells, researchers have improved a method in rodent models intended to help keep children healthy.
DALLAS – May 10, 2021 – Scientists at UT Southwestern have discovered a key protein that helps the bacteria that causes Legionnaires’ disease to set up house in the cells of humans and other hosts. The findings, published in Science, could offer insights into how other bacteria are able to survive inside cells, knowledge that could lead to new treatments for a wide variety of infections.
A neurologic pathway by which non-damaging but high frequency brain impact blunts normal brain function and causes long-term problems with learning and memory has been identified. The finding suggests that tailored drug therapy can be designed and developed to reactivate and normalize cognitive function, say neuroscientists at Georgetown University Medical Center.
A University of Kentucky College of Medicine professor has been awarded a $1.9 million NIH grant for his research on the body’s immune response to sepsis, which could potentially help to improve therapies for the common disease.
St. Jude Children’s Research Hospital scientists have developed a highly efficient method to address a major challenge in biology—identifying the genetic ‘switches’ that regulate gene expression.
Researchers have been awarded a $3.1 million grant from the National Institutes of Health to investigate more effective ways to identify ovarian cancer earlier.
Current guidelines for managing osteoporosis specifically call out hip or spine fractures for increasing the risk for subsequent bone breaks. But a new UCLA-led study suggests that fractures in the arm, wrist, leg and other parts of the body should also set off alarm bells.A fracture, no matter the location, indicates a general tendency to break a bone in the future at a different location.
Researchers at UC San Diego have used gene therapy to prevent learning and memory loss in a mouse model of Alzheimer’s disease, a key step toward eventually testing the approach in humans with the neurodegenerative disease.
Next-generation gene sequencing (NGS) technologies —in which millions of DNA molecules are simultaneously but individually analyzed— theoretically provides researchers and clinicians the ability to noninvasively identify mutations in the blood stream. Identifying such mutations enables earlier diagnosis of cancer and can inform treatment decisions. Johns Hopkins Kimmel Cancer Center researchers developed a new technology to overcome the inefficiencies and high error rates common among next-generation sequencing techniques that have previously limited their clinical application.
Rajesh Kumar, MD, and Jacqueline Pongracic, MD, from Ann & Robert H. Lurie Children’s Hospital of Chicago received $3 million from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) for a site-specific clinical trial on whether a soy supplement in infancy can prevent asthma in children with a high-risk genetic variation. This will be one of the earliest precision medicine approaches to asthma prevention.
A new study, presented today at the AATS 101st Annual Meeting, finds that AATS Foundation fellowships support success in academic surgery career tracks.
DALLAS – April 30, 2021 – UT Southwestern scientists successfully employed a new type of gene therapy to treat mice with Duchenne muscular dystrophy (DMD), uniquely utilizing CRISPR-Cas9-based tools to restore a large section of the dystrophin protein that is missing in many DMD patients. The approach, described online today in the journal Science Advances, could lead to a treatment for DMD and inform the treatment of other inherited diseases.
The National Institute of Allergy and Infectious Diseases, NIAID, part of the National Institutes of Health, NIH, has awarded $2.5 million in grants to support research on bacteriophage therapy, and Texas A&M AgriLife Research is among the grant recipients.
Tiny molecules called nanobodies, which can be designed to mimic antibody structures and functions, may be the key to blocking a tick-borne bacterial infection that remains out of reach of almost all antibiotics, new research suggests.
Asthma exacerbations rose following a catastrophic Christmas Eve fire that destroyed pollution controls at the Clairton Coke Works – the largest such facility in the nation, a University of Pittsburgh Graduate School of Public Health analysis concludes.
DALLAS – April 27, 2021 – Researchers with the Peter O’Donnell Jr. Brain Institute at UT Southwestern have identified a new protein implicated in cell death that provides a potential therapeutic target that could prevent or delay the progress of neurodegenerative diseases following a stroke.
When combined with drugs currently used to treat hepatitis C, the antiviral remdesivir is 10 times more effective in treating cells infected with SARS-CoV-2, the virus that causes COVID-19.
New research from the University of Virginia School of Medicine has shed light on the No. 1 cause of epilepsy deaths, suggesting a long-sought answer for why some patients die unexpectedly following an epileptic seizure.
The New Jersey State Cancer Registry (NJSCR), under the direction of the State Department of Health in partnership with Rutgers Cancer Institute of New Jersey, has been awarded a seven-year, $9,085,109 contract (75N91021D00009) from the National Cancer Institute (NCI) to support core infrastructure and research activities as part of the Surveillance, Epidemiology, and End Results (SEER) Program, the most authoritative source of information on cancer incidence and survival in the United States. The funding will support ongoing cancer surveillance activities at the NJSCR, as well as support enhancements to New Jersey’s electronic reporting systems such as electronic pathology and medical claims data transmissions.
A combination of inexpensive oral medications may be able to treat fatigue-inducing anemias caused by chronic diseases and inflammation, a new discovery from the University of Virginia School of Medicine suggests.
David Goldberg, M.D., M.S.C.E., associate professor of medicine in the Division of Digestive Health and Liver Diseases at the University of Miami Miller School of Medicine, is one of three principal investigators of a five-year, $7.8 million National Institutes of Health-funded study using donor kidneys infected with hepatitis C (HCV) in patients awaiting kidney transplants who do not have HCV.
As regenerative therapies for blinding diseases move closer to clinical trials, the National Eye Institute’s functional imaging consortium, a part of the NEI Audacious Goals Initiative (AGI), is pioneering noninvasive technologies to monitor the function of the retina’s light-sensing neurons and their connections to the brain.
In the first clinical trial of nicotinamide mononucleotide (NMN), researchers at Washington University School of Medicine in St. Louis have found that the compound previously demonstrated to counteract aspects of aging and improve metabolic health in mice also has clinically relevant effects in people.
The Johns Hopkins Malaria Research Institute at the Johns Hopkins Bloomberg School of Public Health will host its annual World Malaria Day Symposium this Friday, April 23, from 9 a.m. to 5:30 p.m. EDT.
Using a widely known field of mathematics designed mainly to study how digital and other forms of information are measured, stored and shared, scientists at Johns Hopkins Medicine and Johns Hopkins Kimmel Cancer Center say they have uncovered a likely key genetic culprit in the development of acute lymphoblastic leukemia (ALL).
A high daily dose of an omega-3 supplement may help slow the effects of aging by suppressing damage and boosting protection at the cellular level during and after a stressful event, new research suggests.
A fetal intervention team led by Ramesha Papanna, MD, MPH, of The University of Texas Health Science Center at Houston (UTHealth) has received a $3.2 million award from the National Institutes of Health (NIH) for preclinical research on a new approach to repair spina bifida in utero.
A Penn Medicine patient with a genetic form of childhood blindness gained vision, which lasted more than a year, after receiving a single injection of an experimental RNA therapy into the eye.
In a study by Yale Cancer Center, researchers report on the discovery of a common mechanism that promotes both autoimmune diseases and blood cancers, including the blood diseases Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL).
Two University of Colorado Cancer Center researchers have received a five-year R01 Award for $497,893 per year from the National Institutes of Health (NIH) to study a potential new drug treatment for salivary gland cancer. The award is part of an inter-campus collaboration between Antonio Jimeno, MD, PhD, co-leader of the Developmental Therapeutics Program, and Tin Tin Su, PhD, co-leader of the Molecular and Cellular Oncology Program.
The National Institutes of Health has awarded the University of Georgia a contract to establish the Center for Influenza Disease and Emergence Research (CIDER). The contract will provide $1 million in first-year funding and is expected to be supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, for seven years and up to approximately $92 million.
The lab of Rahima Benhabbour, PhD, has received a $3.74 million grant over five years from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant will fund the creation of an injectable that will provide long-acting protection for women against sexually transmitted pathogens and prevent pregnancy, but is also removable.
Scientists have discovered a molecular pathway that counteracts the ability of some viruses to evade the immune response. The findings raise hope in generating better immune responses to viral infections, such as COVID-19, as well as to cancer.
Penn Medicine has been selected as one of five sites across the country to serve as a Center of Excellence for Influenza Research and Response (CEIRR), with the goal of better understanding influenza viruses around the world along with learning about the viral strains that have the potential to cause pandemics. Penn Medicine has been awarded nearly $7 million in first-year funding.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that two existing drug candidates—JAK inhibitors and Mepron—hold potential as treatments for a deadly acute myeloid leukemia (AML) subtype that is more common in children. The foundational study, published in the journal Blood, is a first step toward finding effective treatments for the hard-to-treat blood cancer.
In a new Cell Reports study, researchers at La Jolla Institute for Immunology demonstrate how Ebola virus has found a different way to get things done. The virus encodes only eight proteins but requires dozens of functions in its lifecycle. The new study shows how one of Ebola virus’s key proteins, VP40, uses molecular triggers in the human cell to transform itself into different tools for different jobs.
Research to Prevent Blindness and The Glaucoma Foundation are pleased to announce a new round of grants, the Career Advancement Awards (CAAs), that support early-career researchers as they seek new knowledge related to eye diseases.
Researchers from North Carolina State University have found a way to fine-tune the molecular assembly line that creates antibiotics via engineered biosynthesis.
NIH supported early testing of the artificial retina. Now, scientists are testing whether manufacturing it on the International Space Station results in a viable treatment for people with blinding eye diseases.
After a team of researchers showed that a certain enzyme’s presence in cartilage increased significantly in people with osteoarthritis, they targeted it with specially-loaded nanoparticles that stopped the disease’s progression in its tracks.
In a series of experiments that began with amoebas — single-celled organisms that extend podlike appendages to move around — Johns Hopkins Medicine scientists say they have identified a genetic pathway that could be activated to help sweep out mucus from the lungs of people with chronic obstructive pulmonary disease a widespread lung ailment.
A chemical modification of RNA that can be influenced by diet appears to play a key role in polycystic kidney disease, an inherited disorder that is the fourth leading cause of kidney failure in the U.S., UT Southwestern researchers report in a new study. The findings, published online today in Cell Metabolism, suggest new ways to treat this incurable condition.
In a medical records study covering thousands of children, a U.S.-Canadian team led by researchers at Johns Hopkins Medicine concludes that while surgery to correct congenital heart disease (CHD) within 10 years after birth may restore young hearts to healthy function, it also may be associated with an increased risk of hypertension — high blood pressure — within a few months or years after surgery.